A Phase 2a, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of ADL5859 and ADL5747 in Subjects With Moderate to Severe Pain Due to Osteoarthritis of the Knee.

Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of ADL5859 and ADL5747 in Subjects With Moderate to Severe Pain Due to Osteoarthritis of the Knee.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs ADL 5747 (Primary) ; ADL 5859 (Primary) ; Oxycodone
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Adolor Corporation
  • Most Recent Events

    • 18 May 2017 According to Media Release (9130098), Cubist Pharmaceuticals acquired Adolor Corporation on 24 Oct 2011 and trial was completed on Jun 2010 . kindly, do not add Cubist in association field.
    • 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jun 2010 Disappointing top-line results have been reported in an Adolor corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top